| Opening of Offer to Buy – Acquisition Window (Buyback) for Jenburkt Pharmaceuticals Limited |
Trading Members and Custodians are requested to note that Securities Exchange Board of India (SEBI) has issued Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, Buy Back and vide its circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 and no. CFD/DCR2/CIR/P/2016/131 dated Dec 09, 2016. The Exchange vide its notice no. 20170210-16 dated Feb 10, 2017, has issued Revised Guidelines of Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, Buy Back and Delisting.
All Market Participants are hereby informed that Jenburkt Pharmaceuticals Limited (“Company”), has announced cash offer for Buyback not exceeding 2,08,333 (Two Lakh Eight Thousand Three Hundred And Thirty Three only) fully paid-up equity shares of face value Rs 10/- each, representing 4.48% of the total number of equity shares in the Issued, Subscribed and Paid-Up Equity share capital of the Company, from all the eligible shareholders / beneficial owners of equity shares of the Company registered as on the Record Date i.e. 10th November, 2017, on a proportionate basis, through the “Tender Offer” process at a price of Rs 576 (Rupees Five Hundred And Seventy Six only) per equity share for an aggregate amount of Rs 11,99,99,808 (Rupees Eleven Crore Ninety Nine Lakh Ninety Nine Thousand Eight Hundred And Eight only), from December 06, 2017 to December 19, 2017.
Market participants are further requested to note that this offer will be as per the Revised Guidelines of SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated Dec 09, 2016 and Exchange notice no. 20170210-16 dated Feb 10, 2017 and the details of this Offer to Buy would be available on BSE Website – www.bseindia.com.
Bhushan Mokashi
Addl. General Manager
Listing Sales & Ops
December 01, 2017
|